Heart Failure Society of America AHFTC Board Certification Review 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Cardiologists, Heart Failure Specialists, Transplant Clinicians, Cardio-Oncologists, Nephrologists, Pulmonologists, Immunologists, Geneticists

+ Sample video: contact me for sample video

+ Information:

The HFSA AHFTC Board Certification Review 2026 is a focused, two-day educational program that will take place from July 17–18, 2026, in Chicago, IL, at the Hilton Rosemont/Chicago O’Hare. Designed by leading experts, this live, in-person course delivers high-yield, practical education that is directly aligned with the official ABIM exam blueprint and addresses the real-world challenges of managing patients with advanced heart failure. In addition to the live sessions, registration includes a robust bundle of supplemental study resources, such as pre-meeting OnDemand webinars, a curated reading list, and the HFSA ABIM AHFTC Question Bank, creating a complete learning system for preparation before, during, and after the course.

Learning Objectives

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

• Review testable content and the focus of the ABIM Advanced Heart Failure and Transplant Cardiology Certification Examination.

• Identify gaps in knowledge about advanced heart failure and transplant cardiology.

• Explain how to best focus study efforts on filling identified knowledge gaps.

• Provide practice for the certification examination with ABIM-style multiple-choice test questions.

For Clinical Practice:

• Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure.

• Discuss the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms.

• Assess and treat patients with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.

• Apply guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices.

• Incorporate appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, valvular heart disease, pregnancy-associated disease, and cardiorenal syndrome.

• Explain the genetic basis of cardiomyopathies, including hypertrophic cardiomyopathy, and recognize when to pursue genetic testing as part of the evaluation of patients with suspected inherited heart failure syndromes.

• Manage comorbidities in patients with chronic heart failure, including sleep-disordered breathing, anemia, and diabetes.

• Implement strategies for effective disease management of patients with advanced heart failure, including referral for mechanical circulatory support, heart transplant, or palliative care.

• Manage immunosuppressive therapies and common complications of heart transplant, including rejection, allograft vasculopathy, and immunosuppression-associated conditions.

• Utilize mechanical support devices, both temporary and durable.

• Manage common complications of mechanical circulatory support.

Target Audience

• This program is ideal for: Physicians preparing for the ABIM AHFTC Board Certification or MOC exams. Cardiologists, HF specialists, and transplant clinicians seeking high-level clinical updates. Advanced practice providers and multidisciplinary HF team members who want comprehensive, practical education in advanced heart failure and transplant care.
• Best for Cardiologists, Heart Failure Specialists, Transplant Clinicians, Cardio-Oncologists, Nephrologists, Pulmonologists, Immunologists, Geneticists, and Obstetricians/Gynecologists.

Topics

OnDemand Content / Core Board Prep:

• Cardio-Oncology for the HF Boards.

• Clinico-Pathologic Correlates in Heart Failure / Images for the Heart Failure Boards.

• Managing the Cardiovascular-Kidney Metabolic Syndrome in Patients with Heart Failure.

• Diagnosis and Clinical Assessment.

• Healthcare Disparities in HF.

• Heart Failure Epidemiology and Risk Factors.

• Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions).

• Management of Comorbidities in Heart Failure – Sleep Disorders.

• Pathophysiology 1: Cellular and Energetic Considerations.

• Pathophysiology 2: Hemodynamic, Structural and Neurohormonal Considerations.

• Pulmonary Hypertension: Classification and Initial Evaluation.

• RV Failure and TR Management.

• Statistics for the HF Board.

Live Program – Day 1 (Friday, July 17, 2026):

• Live ABIM Style Question Session.

• Hemodynamics in HF.

• Optimal Medical Therapy for HFrEF.

• Cardio Renal Failure Interactions in Heart Failure.

• Assessment of Functional Capacity Including CPET.

• HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (For the Boards).

• Management of Comorbidities in Heart Failure: Iron Deficiency/Anemia.

• Specific Etiologies of HF 1: HCM (Hypertrophic Cardiomyopathy).

• Specific Etiologies of HF 2: Other Inherited HF syndromes.

• Specific Etiologies of HF 3: Infiltrative Disorders and Restrictive CMP.

• Specific Etiologies of HF 4: Myocarditis and Inflammatory Cardiomyopathies.

• Management of the Hospitalized HF Patient.

• Management of Left Sided Valvular Heart Disease in Heart Failure.

• Management of Common Arrhythmias 1 & 2.

Live Program – Day 2 (Saturday, July 18, 2026):

• Welcome & Live ABIM Style Question Session.

• Adult Congenital Heart Disease for the HF Specialist.

• Pregnancy in HF.

• Immunology: The Basics, PRA, Sensitization, Crossmatch.

• Rejection: Cellular and Antibody Mediated.

• Heart Transplant, Clinical Outcomes and Complications.

• Managing Immunosuppression and Drugs.

• Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies.

• Cardiogenic Shock Management.

• Device Therapy in Heart Failure I: Sudden Death Prevention.

• Device Therapy in Heart Failure II: CRT (Cardiac Resynchronization Therapy).

• MCS 1: Durable MCS Devices and Outcomes.

• MCS 2: Temporary Support Devices and ECMO for the Boards.

• MCS 3: Management of Complications of MCS.

• MCS 4: Interactive Shock and Device Management.